GNOM vs IHI

Key Takeaways

• Global X Genomics & Biotechnology ETF (GNOM) offers targeted exposure to genomics and biotechnology companies through the Solactive Genomics Index, while iShares U.S. Medical Devices ETF (IHI) tracks the Dow Jones U.S. Select Medical Equipment Index for focused medical device and equipment manufacturers.
• GNOM maintains approximately 50 holdings with an expense ratio of 0.50%, emphasizing innovative gene editing, sequencing, and genetic therapies; IHI holds around 50 positions with a lower 0.37% expense ratio, concentrating on established device makers.
• Top holdings in GNOM include MRNA, TWST, and TXG, reflecting higher thematic volatility, whereas IHI features ABT, ISRG, and MDT for more stable sector representation.
• Both ETFs operate as passive strategies within healthcare but differ in risk profiles: GNOM pursues high-growth thematic opportunities with greater concentration in emerging biotech, while IHI provides broader, lower-cost access to durable medical equipment trends.
• Structural differences in rebalancing (semi-annual for GNOM, quarterly for IHI) and geographic focus influence liquidity and positioning, with IHI demonstrating larger assets under management and tighter bid-ask spreads.
• Investors seeking cost efficiency and established device exposure may favor IHI, while those targeting genomics innovation may consider GNOM despite elevated fees and narrower scope.

Introduction

Global X Genomics & Biotechnology ETF (GNOM) and iShares U.S. Medical Devices ETF (IHI) represent distinct approaches to healthcare sector exposure. They do not compete directly but offer alternative strategies within the broader life sciences and medical technology landscape. GNOM targets companies advancing genomic science, including gene editing and computational biology, while IHI focuses exclusively on U.S. manufacturers and distributors of medical devices and equipment. This comparison helps investors evaluate thematic innovation versus established sector infrastructure amid ongoing advancements in personalized medicine and healthcare technology adoption.

Global X Genomics & Biotechnology ETF (GNOM) Overview

Global X Genomics & Biotechnology ETF (GNOM) is a passively managed thematic ETF that seeks to track the Solactive Genomics Index. The index selects up to 50 companies deriving significant revenue from genomics-related activities such as gene editing, genomic sequencing, genetic medicine and therapies, computational genomics, and genetic diagnostics. The fund holds approximately 50 securities and charges a total expense ratio of 0.50%. Top holdings typically include Moderna Inc. (MRNA), Twist Bioscience Corp. (TWST), 10x Genomics Inc. (TXG), Illumina Inc. (ILMN), and Natera Inc. (NTRA). Nearly all assets reside in healthcare, with semi-annual index reconstitution and rebalancing. GNOM provides global exposure with a focus on high-growth, innovation-driven biotechnology firms.

iShares U.S. Medical Devices ETF (IHI) Overview

iShares U.S. Medical Devices ETF (IHI) is a passively managed sector ETF designed to track the Dow Jones U.S. Select Medical Equipment Index. The index comprises U.S.-listed companies primarily engaged in manufacturing and distributing medical devices and equipment. The fund holds approximately 50 securities and maintains a total expense ratio of 0.37%. Leading holdings generally feature Abbott Laboratories (ABT), Intuitive Surgical Inc. (ISRG), Medtronic Plc (MDT), Stryker Corp. (SYK), and IDEXX Laboratories Inc. (IDXX). The portfolio allocates essentially 100% to healthcare equipment, with quarterly rebalancing to maintain market-cap weighting and constituent caps. IHI emphasizes established domestic device manufacturers with substantial assets under management supporting strong liquidity.

Industry and Thematic Backdrop

The healthcare sector continues to benefit from structural tailwinds including aging populations, rising demand for minimally invasive procedures, and technological integration in diagnostics and treatment. Genomics and biotechnology innovation face regulatory pathways for novel therapies alongside capital investment in precision medicine. Medical device manufacturers navigate supply chain stabilization, reimbursement dynamics, and adoption of robotic and digital health solutions. Macroeconomic factors such as interest rate expectations influence growth-oriented biotech valuations more acutely than mature device companies. Regulatory developments around genetic therapies and device approvals remain key catalysts, while sector risks include clinical trial outcomes, competitive pressures, and healthcare policy shifts.

Performance and Positioning Comparison

In recent market cycles, Global X Genomics & Biotechnology ETF (GNOM) has exhibited higher volatility tied to biotechnology earnings cycles and sentiment around genomic breakthroughs. iShares U.S. Medical Devices ETF (IHI) has demonstrated more consistent positioning linked to steady procedural volumes and device utilization trends. Relative performance has reflected sector rotation favoring established equipment providers during periods of economic uncertainty, while GNOM has captured upside from innovation announcements. Both ETFs respond to broader healthcare spending patterns, though IHI's larger scale and lower expense ratio support tighter tracking and liquidity during volatile periods.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener to uncover additional opportunities aligned with your investment criteria.

Tickeron AI Verdict

Based on observable structural factors including lower expense ratio, greater assets under management, diversified holdings within a stable subsector, and consistent liquidity profile, Tickeron’s AI would currently assign a higher probabilistic preference to iShares U.S. Medical Devices ETF (IHI) for most investors seeking balanced healthcare equipment exposure. Global X Genomics & Biotechnology ETF (GNOM) may appeal in scenarios prioritizing thematic genomics momentum despite elevated costs and narrower focus.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations